study

Avextra Backs Landmark Psilocybin Therapy Study in Palliative Care

December 20, 2024 12:00 ET  | Source: Avextra Pharma GmbH News Release Exclusive Industry Role: Avextra is the industry partner…

2 days ago

Myriad Genetics RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic…

3 days ago

IBM Study: Vehicles Believed to be Software Defined and AI Powered by 2035

ARMONK, N.Y., Dec. 12, 2024 /PRNewswire/ -- The IBM (NYSE: IBM) Institute for Business Value today published its latest 'Automotive…

5 days ago

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Tuesday, December 17, 2024 at 8:00 am EST December 16, 2024 18:15 ET  | Source: Biomea Fusion, Inc. REDWOOD CITY,…

5 days ago

IBM Study: Vehicles Believed to be Software Defined and AI Powered by 2035

ARMONK, N.Y., Dec. 12, 2024 /PRNewswire/ -- The IBM (NYSE: IBM) Institute for Business Value today published its latest 'Automotive…

6 days ago

IBM Study: Vehicles Believed to be Software Defined and AI Powered by 2035

ARMONK, N.Y., Dec. 12, 2024 /PRNewswire/ -- The IBM (NYSE: IBM) Institute for Business Value today published its latest 'Automotive…

7 days ago

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast…

1 week ago

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast…

1 week ago

IBM Study: Vehicles Believed to be Software Defined and AI Powered by 2035

ARMONK, N.Y., Dec. 12, 2024 /PRNewswire/ -- The IBM (NYSE: IBM) Institute for Business Value today published its latest 'Automotive…

1 week ago

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast…

1 week ago